NSI Rising Stars in Immunology Seminar Series
Initiated in 2021, the NSI Rising Stars in Immunology Seminar Series invites world-leading young PIs from all over the world working in the field of immunology to present their research to NSI members
Please send us your suggestions for future speakers! We are striving for a broad coverage of immunology topics, geographical locations as well as gender balance.
Send speaker suggestions to Victor Greiff: firstname.lastname@example.org
Speaker: Helene Knævelsrud
Title: Exploring the human leukemic oncogene MLL-AF4 in the fruit fly blood system and fat tissue
Time and date: Tuesday, 29th August 2023, at 14:00
Meeting ID: 695 3535 1721
More information about Helene:
Dr. Helene Knævelsrud leads the research group “Cell stress and Cancer” as associate professor at Institute for Basic Medical Sciences, University of Oslo. The group is focused on two main goals:
1) to understand how autophagy is switched off in vivo and
2) to unravel mechanisms of autophagy involvement in cancer biology For this the group is using Drosophila melanogaster as a model organism for hematopoiesis and leukemia.
Dr. Knævelsrud graduated in Cellular Biochemistry from ETH Zürich and obtained her PhD in Biochemistry from the University in Oslo. Under the supervision of Professor Anne Simonsen she studied the role of lipid-binding proteins in autophagy. During a research visit to Professor Tom Neufeld’s lab at the University of Minnesota, she fell in love with fruit flies. Therefore, she pursued postdoctoral research in the lab of Professor Marc Therrien at Université de Montréal working on small GTPases in hematopoietic development, using Drosophila as a model organism. In 2015 Dr. Knævelsrud joined the lab of Professor Jorrit Enserink with her project on a fly leukemia model. She established her own project group in 2020 to work on autophagy termination in physiology and in cancer, especially in renal cell carcinoma. She is leader of AUTORHYTHM, an interdisciplinary environment at the University of Oslo aimed at understanding the role of autophagy in healthy aging. In 2022 Dr. Knævelsrud was awarded an ERC Starting Grant to study how autophagy is turned off and how this is orchestrated at the organism-level and in 2023 she started at Associate Professor at University of Oslo. Dr. Knævelsrud has written regularly in national newspapers and presented at multiple popular science fairs. She is an NCMM Young Investigator and elected member of the Young Academy of Norway.
- Johannessen, J.A., Formica, M., Bråthen, N.R., Al Outa, A., Enserink, J.M. and Knævelsrud, H.* The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae bioRxiv 2022.11.08.515565; https://doi.org/10.1101/2022.11.08.515565 In revision in iScience August 2023
- Formica M, Storaci AM, Bertolini I, Carminati F, Knævelsrud H, Vaira V, Vaccari T. (2021) V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis. Autophagy. May 12:1-11.
- Baril, C., Gavoy, G., Bidla, G., Knævelsrud H., Sauvageau, G., Therrien, M. (2017) Human NUP98-HOXA9 promotes hyperplastic growth of hematopoietic tissues in Drosophila. Dev Biol. 421(1):16-26
Speaker: Janine Melson
Title: A multicolor map of NK and T cell diversity: from bulk to single-cell
Time and date: Tuesday, 20th June 2023, at 14:00
Connection details: https://uio.zoom.us/j/64034045614?pwd=NGxyZ01IeVlQeENBRE9tZWdndldSZz09
Meeting ID: 640 3404 5614
More information about Janine:
Dr. Janine Melsen is a post-doctoral researcher at the department of Immunology, and Willem-Alexander Children’s Hospital at the Leiden University Medical Center, in the Netherlands. Although she is a biomedical scientist by training, she acquired bioinformatic skills during her PhD and considers herself now both as wet lab and dry lab scientist. Her PhD project focused on unraveling the function and development of human tissue-resident NK cells, in relation to circulating NK cells, using bulk and single-cell RNA sequencing, and (spectral) flow cytometry. To uncover the cellular heterogeneity, she wrote a workflow to analyze flow cytometry data at the single-cell level. Using this workflow, she simultaneously studied the T cell phenotype and receptor diversity of the first European hematopoietic stem cell transplant recipient revealing clonal T cell expansions, persisting for more than a decade. Her current research focuses on human NK cell development in thymus and tonsil. She recently visited the lab of Emily Mace In New York (Columbia University) where she mastered the technique of cyclic immunofluorescence to study the spatial organization of NK developmental niches.
- Melsen JE, van Ostaijen-Ten Dam MM, Schoorl DJA, Schol PJ, van den Homberg DAL, Lankester AC, Lugthart G, Schilham MW. Single-cell transcriptomics in bone marrow delineates CD56dimGranzymeK+ subset as intermediate stage in NK cell differentiation. Front Immunol. 2022 Nov 24;13:1044398. https://pubmed.ncbi.nlm.nih.gov/36505452/
- Melsen JE, van Ostaijen-Ten Dam MM, van den Akker EB, Welters MJP, Heezen KC, Pico-Knijnenburg I, Kolijn PM, Bredius RGM, van Doorn R, Langerak AW, Schilham MW, Lankester AC. T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation. J Clin Immunol. 2022 Aug;42(6):1205-1222. https://pubmed.ncbi.nlm.nih.gov/35527320/
- Melsen JE, van Ostaijen-Ten Dam MM, Lankester AC, Schilham MW, van den Akker EB. A Comprehensive Workflow for Applying Single-Cell Clustering and Pseudotime Analysis to Flow Cytometry Data. J Immunol. 2020 Aug 1;205(3):864-871. https://pubmed.ncbi.nlm.nih.gov/32591399/
Speaker: Saba Ghassemi
Title: Non-Activated CAR T Cells for Cancer Immunotherapy
Time and date: Tuesday, 2nd May 2023, at 14:00
Connection details: https://uio.zoom.us/j/67567030388?pwd=MWpyOXdVTE1GTWg4UWpvdjhxRUxIdz09
Meeting ID: 675 6703 0388
More information about Saba:
Dr. Saba Ghassemi is an assistant professor in the Department of Pathology and Lab Medicine at the University of Pennsylvania and a Principal Investigator at the Center for Cellular Immunotherapies. Her research focuses on optimizing CAR T cells for adoptive immunotherapy, using a multidisciplinary approach that combines engineering with CAR T cell immunology to develop potent CAR T cells. Dr. Ghassemi was the first to develop an abbreviated culture paradigm, leading to less differentiated progeny with improved potency in xenograft models of ALL, which resulted in a successful clinical trial at UPenn using a 3-day manufacturing process. She employs advanced techniques to abbreviate the ex vivo CAR T cell culture process to less than 24 hours. Dr. Ghassemi’s work has been recognized through several research grants and patent applications to improve CAR T cells’ efficacy, expansion, and fitness for adoptive immunotherapy. Dr. Ghassemi’s ongoing research endeavors involve optimizing, streamlining, and automating the manufacturing process of CAR T cells, with the ultimate goal of enhancing the translational applicability and accessibility of these novel therapies to a wider range of geographical locations and patient populations.
Rapid manufacturing of non-activated potent CAR T cells
S Ghassemi, JS Durgin, S Nunez-Cruz, J Patel, J Leferovich, M Pinzone, …
Nature biomedical engineering 6 (2), 118-128
395 Engineering non-activated CAR T cells with enhanced potency against advanced cancers
S Ghassemi, J Durgin, F Bushman, S Gill, R O’Connor, M Milone
Journal for ImmunoTherapy of Cancer 10 (Suppl 2)
Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design
S Ghassemi, FJ Martinez-Becerra, AM Master, SA Richman, D Heo, …
Molecular Therapy-Methods & Clinical Development 18, 595-606
Speaker: Aleksandar Antanasijevic, EPFL, CH
Title: Antibody responses visualized by electron microscopy: Structure, sequence and beyond…
Time and date: Tuesday, 4th April 2023, at 14:00.
Meeting ID: 616 2156 6954
More information about Aleksandar:
Bio: Aleksandar Antanasijevic is a biochemist by training, with a strong research background in structural biology and its application to virus and vaccine research. He completed his PhD at the University of Illinois at Chicago in the lab of Michael Caffrey, where he first got exposed to methods like nuclear magnetic resonance and X-ray crystallography. Following a postdoc in Andrew Ward’s lab at the Scripps Research Institute, where he specialized in electron microscopy, he moved to EPFL to start his own research group. In his new lab, he seeks to establish a multi-component research program to aid structure-guided vaccine design efforts in different fields using electron microscopy as the primary tool.
- https://www.science.org/doi/full/10.1126/sciadv.abk2039: From structure to sequence: Antibody discovery using cryoEM
- https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008665: Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens
Speaker: Encarnita Mariotti-Ferrandiz Sorbonne Université, Paris, France
Title: Low-dose IL2 restores Treg antigen-specific TCR repertoire in mice and autoimmune disease patients
Time and date: Wednesday, 22nd March 2023, at 14:00.
Meeting ID: 641 5607 6300
More information about Encarnita:
Bio: Encarnita Mariotti-Ferrandiz is Associate Professor in Immunology at Sorbonne Université and a senior member of the fundamental chair at Institut Universitaire de France, working as PI in the immunology-immunopathology-immunotherapy (i3) lab, located at Pitié-Salpêtrière Hospital, in Paris. Her research focuses on i) deciphering the Adaptive Immune Receptor Repertoire (AIRR) diversity in health and pathology with a major focus on T-cell biology and ii) developing a systems immunology approach to better characterize the immune system in disease by coordinating the integration of multi-scale biological (deep cell phenotype, transcriptome, adaptome, microbiome) and clinical information. From sample to statistical modelling, she is interested in (i) refining T cell differentiation and selection knowledge in health and disease and (ii) identifying uni-modal and multi-modal biomarkers of diseases. Her main field of research in immunology focus on the study of autoimmune in inflammatory diseases. She is involved in national projects (Transimmunom LabEx, iMAPRHU) as well as PI in international collaborative projects (AIR-MI and iReceptorPlus). More details on her publications and projects here. As Associate-Professor, she created and launched in 2019 thefirst “Integrative and systems Immunology” Master 2 curriculum at Sorbonne Université, with the aim to promote systems immunology as a whole, including AIRR field.
- Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases: https://www.nature.com/articles/s41587-020-0656-3
- Polyclonal expansion of TCR Vβ 21.3+ CD4+ and CD8+ T cells is a hallmark of multisystem inflammatory syndrome in children: https://www.science.org/doi/full/10.1126/sciimmunol.abh1516
- Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling: https://elifesciences.org/articles/66274
Speaker: Paul Bastard Necker Hospital for Sick Children, Paris, France
Title: Genetic and auto-immune predisposition to life-threatening COVID-19
Time and date: Tuesday, 21st Feb 2023, at 14:00.
Teams link (click the link even though it is in Norwegian):
Klikk her for å bli med i møtet
Meeting-ID: 374 766 685 678
Bio: Paul Bastard, MD-PhD, is currently working as a fellow in the Pediatric Hematology and Immunology department of Necker Hospital for Sick Children (AP-HP, Paris, France), while also doing research in the Necker branch of the laboratory of Jean-Laurent Casanova, which is located at the Imagine Institute (University of Paris and INSERM) and the Rockefeller University (New York, USA). His research focuses on the genetic and immunological determinants of severe viral diseases, including the causes and consequences of auto-antibodies against type I interferons.
Speaker: Dr. Amalie Kai Bentzen from the Technical University of Denmark.
Title: Interrogating T cell recognition across cancers, infections and autoimmune diseases using MHC multimers labeled with DNA barcodes
Talk coordinates: 17th Jan 2023, at 14:00.
Zoom link: https://uio.zoom.us/j/64133018041?pwd=Q0V5SHZaSzFvNVpxdFVXSmQ0dDFDdz09
Meeting ID: 641 3301 8041
Bio: Amalie Kai Bentzen is a Postdoc in the Section of Experimental and Translational Immunology at the Technical University of Denmark. She has a BSc in Biotechnology and a MSc in Human Biology both from the University of Copenhagen, Denmark. She started doing research in Immunology and Cancer during her Master’s in her thesis work at the Danish National Center for Cancer Immune Therapy (CCIT-DK). This would be the start of her efforts towards developing high-throughput strategies for interrogating CD8 T cell recognition. She has made her Phd in Sine Reker Hadrup’s lab at the Technical University of Denmark, where she has developed DNA barcode-based MHC multimer approaches for understanding CD8 T cell recognition, initially in melanoma and lung cancer, but later in a broader range of diseases. During her Postdoc in the same lab, she has focused on mapping T cell recognition on a single-cell level to track the TCR and clonal origin of disease relevant T cells.
Speaker: Dr. Jenna Guthmiller (University of Colorado School of Medicine.)
“Humoral Immunity against Influenza Viruses: The Good, The Bad,
and The Ugly”
Talk coordinates: Wednesday, September 21st 2022, at 14.30.
Meeting ID: 649 4022 5066
Bio: Dr. Jenna Guthmiller is an Assistant Professor in the Department of Immunology and Microbiology at the University of Colorado Anschutz Medical Campus. Jenna received her PhD from the University of Oklahoma Health Sciences Center in 2017, where she studied the regulation of humoral immunity against blood-stage Plasmodium parasites under the mentorship of Dr. Noah Butler. She went on to perform her postdoctoral training in the laboratory of Dr. Patrick Wilson at the University of Chicago, where she shifted her focus towards understanding B cell specificities against influenza viruses. As a new investigator, her group studies the specificities, function, and evolution of broadly protective antibody responses against influenza viruses and how vaccination can induce a robust broadly protective antibody response.
Some key papers:
- Guthmiller JJ*†, Han J, […], Ward AB†, Wilson PC†. Broadly neutralizing antibodies target a hemagglutinin anchor epitope. Nature. 2022
- Guthmiller JJ, Lan YL, Fernández-Quintero M, Han J, Bitar D, Hamel N, Stovicek O, Li L, Tepora M, Henry C, Neu K, Dugan H, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AKE, García-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl K, Wilson PC†. Polyreactive broadly neutralizing B cells are selected to provide defense against pandemic threat influenza viruses. Immunity. 2020
- Google scholar:https://scholar.google.com/citations?user=4arwbfMAAAAJ&hl=en
- Website: https://guthmillerlab.weebly.com/l
Speaker: Dr. Quirin Hammer (Karolinska Institutet)
“NK cell recognition of viruses”
Talk coordinates: Thursday, June 2nd 2022, at 14.00.
Meeting ID: 690 4981 9582
Bio: Dr. Quirin Hammer obtained his PhD in Immunology from Humboldt University in Berlin, Germany in 2018. During his doctoral studies, he investigated how natural killer (NK) cells of the innate immune system respond to different strains of cytomegalovirus under supervision from Prof. Chiara Romagnani at the German Rheumatism Research Center. After his PhD, Quirin joined the Center of Infectious Medicine at the Karolinska Institute in Stockholm, Sweden under the mentorship of Prof. Karl-Johan Malmberg. At KI, Quirin is heading a team exploring the molecular signals that allow NK cells to recognize virus-infected or tumor transformed cells and aims to translate his findings into advancing immunotherapy.
Some key papers:
- SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells, Cell Reports
- Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells, Nature Immunology
- Google scholar:https://scholar.google.ch/citations?user=HJV_po4AAAAJ&hl=en&oi=ao
Speaker: Dr. Feix Hartmann (German Cancer Research Center)
“Single-Cell Proteomics and Multiplexed Imaging to Reveal Metabolic Interactions in the Tumor-Immune Microenvironment”
Talk coordinates: Thursday, March 10 2022, at 14.00.
Meeting ID: 610 9018 1291
Bio: Dr. Felix Hartmann is a Helmholtz Young Investigator German Cancer Research Center (DKFZ), Heidelberg, Germany. He performed his postdoctoral work in the lab of Bendall Lab (Stanford) and his PhD in the Becher lab (University of Zürich). In the Bendall lab, he conceived and implemented a novel approach to quantify cellular metabolism of individual cells using proteomic mass spectrometry-based technologies, established simultaneous metabolic and phenotypic analysis of single cells by mass cytometry (CyTOF) and of human tissues by multiplexed ion beam imaging (MIBI-TOF), and revealed tumor-specific metabolic features of cytotoxic T cells in cancer patients. In the Becher lab, he investigated the regulation of T cell cytokine production as a pathologic mechanism in human multiple sclerosis, conducted proteomic single-cell analysis of large clinical patient cohorts, revealed specific cytokine production profiles as biomarkers of therapeutic success. Among his academic honors and awards are: Helmholtz Young Investigator, Ivring Cancer Immunology Scholar, EMBO Long-term postdoctoral fellowship, AAI Young Investigator Award, Novartis Postdoctoral fellowship, SNF Early Postdoc Fellowship, Pfizer Research Prize.
Some key papers:
- Hartmann FJ, Mrdjen D, McCaffrey E, Glass DR, Greenwald NF, Bharadwaj A, Khair Z, Verberk SGS, Baranski A, Baskar R, Graf W, Van Valen D, Van den Bossche J, Angelo M, Bendall SC (2021). Single-Cell Metabolic Profiling of Human Cytotoxic T Cells. Nature Biotechnology.
- Galli E*, Hartmann FJ*, Schreiner B, …, Olsson T, Becher B (2019). GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nature Medicine.,
- Google scholar:https://scholar.google.ch/citations?user=ElszAVEAAAAJ&hl=en&oi=ao
- Website: https://www.dkfz.de/en/systemimmunologie-und-einzelzell-biologie/index.php ]
Speaker: Dr. Daniela Latorre (ETH Zürich)
“Autoreactive T cells in neurological disorders”
Date: Thursday, Feb 17 2022, at 14.00.
Meeting ID: 688 8582 8043
Bio: Daniela Latorre, Dr. Daniela Latorre is an immunologist at the Institute of Microbiology, ETH Zurich. After obtaining her PhD in Immunology at “Sapienza” University of Rome in Italy, she moved to Switzerland to perform her Postdoctoral training in the laboratory of Prof. Federica Sallusto first at the Institute for Research in Biomedicine (IRB) in Bellinzona and later at the newly established Medical Immunology laboratory at ETHZ. During these years, she focused her studies on several aspects of human T cells biology in physiological and pathological conditions, including autoimmunity and immunodeficiency. Her main postdoctoral work provided the first solid evidence of the autoimmune basis of narcolepsy, a rare neurological disorder (Latorre D et al., Nature, 2018) and opened new perspectives in the field of sleep- related disorders by prompting new studies with major translational implications to the clinics. This research earned her several prizes, including the well-renowned Pfizer Research Prize 2020, the Young Scientist Award 2019 by EU-NN and the Best International Young Researcher on Narcolepsy 2018 by AIN. Since 2019, she has received different research grants, including the highly competitive PRIMA career grant by the Swiss National Science Foundation that allowed her to start an independent career and to establish the Human Neuroimmunology Group at ETH Zurich in January 2020. Her research focuses on the study of human self-reactive T cells in immune-mediated neurological diseases, including Guillain Barré Syndrome and Multiple Sclerosis, with the overall goal to gain knowledge of basic aspects of human T cell biology in health and autoimmunity and then translate those findings into biomedical applications. During the past years, she has been also involved in activities the go beyond the scientific research itself. Since 2020, she has been engaging in the set-up and coordination of the Swiss Young Immunologists Society (SYIS) with the aim to promote scientific exchange, networking and visibility among early career researcher in Switzerland and in Europe.” Google scholar: https://scholar.google.ch/citations?user=26zLt2wAAAAJ&hl=en&oi=ao
Speaker: Dr. Danika Hill
“Studying germinal centre responses to vaccines in humans”
Date: Thursday, Jan 27, 2022 at 10.00.
Meeting ID: 653 0417 2967
Bio: Danika Hill, Group Leader, Precision Vaccines Group Department of Immunology & Pathology, Monash University, Australia. “Danika Hill’s research is focussed on understanding the cellular and molecular mechanisms that underpin robust CD4+ T helper cell responses to vaccination and infection in humans. Danika has a particular interest in targeting T follicular helper cells to improve vaccine responses, measuring T cell receptor repertoire alterations after vaccination, and developing novel methods to identify antigen-specific CD4+ T cells. Danika studied Biomedical Science at the University of Adelaide, and completed a PhD at the Walter and Eliza Hall Institute of Medical Research. From 2015, Danika was a Postdoc at the Babraham Institute in Cambridge, working with Dr Michelle Linterman. She joined the Monash University Department of Immunology and Pathology, working with Professor David Tarlinton, in 2020. In 2020, she received the Michelson Prize from the Human Vaccines Project & Michelson Research Foundation funding for human immunology and vaccine research. Google scholar: https://scholar.google.ch/citationshl=en&user=b63CRhAAAAAJ&view_op=list_works&sortby=pubdate
Speaker: Prof Marcus Buggert
“Resident and recirculating memory CD8+ T cells in health and viral disease”
Date: Thursday, Dec 9 2021, at 14.00.
Meeting ID: 675 2241 1462
Bio: Marcus Buggert, Assistant Professor at the Center for Infections Medicine (CIM), Karolinska Institutet. “Marcus Buggert defended his PhD Thesis in 2014 at the Karolinska Institutet, Sweden on the role of T cells in natural control of HIV infection. He then joined Dr. Michael Betts’ laboratory at University of Pennsylvania in 2014 for post-doctoral studies. During these studies, he pursued multiple projects including the first identification and characterization of resident and recirculating memory T cells in the context of HIV and other human viral infections. Since 2018, he is back in Sweden and joined the Center for Infection Medicine, Karolinska Institutet. The following year he got a centrally-funded faculty position (Assistant Professor) and became a group leader. His group focuses their work on studies of cell-mediated immunity to cancer and viral infections – including HIV and SARS-CoV-2.” Google scholar: https://scholar.google.ch/citations?user=4NbgQ1UAAAAJ&hl=en&oi=ao
Speaker: Prof Dr. Yana Safonova
‘High-throughput profiling of antibody repertoires enables large-scale analysis of adaptive immune responses’
Date: Thursday, Oct 7th, 2021 at 14.00.
Meeting ID: 611 0983 1021
Bio: Prof. Dr. Yana Safonova, is an Incoming Assistant Professor. Department of Computer Science, Johns Hopkins University, USA.. “Currently, I am focusing on open problems in immunogenomics and computational immunology that include applications of the recently emerged immunosequencing technology (or repertoire sequencing) to design of antibody drugs, prediction of vaccine efficacy, and population analysis of the immune loci. Click here to learn more about the research projects.” Google scholar: https://scholar.google.ch/citations?hl=en&user=v1DsRLMAAAAJ
Speaker: Prof Dr. Tobias Lenz ”
Evolutionary genomics of an optimal adaptive immune response – Trade-offs between pathogen resistance and autoimmunity”
Date: Thursday, Sept 30, 2021
Bio: Prof. Dr. Tobias L. Lenz, is Head of Research Unit for Evolutionary Immunogenomics, Institute of Zoology, University of Hamburg, Heisenberg Professorship. “Our research investigates the evolutionary origin and consequences of functional genetic diversity in the context of health and disease. A particular focus of the group lies on the dynamics and trade-offs that govern successful antigen presentation and recognition in the adaptive immune system of vertebrates. We are exploring the complex interactions between the functional variability of antigen-presenting MHC molecules, the dynamics of the interacting T cell repertoire, and the antigen evolution in pathogens in order to improve our understanding of immune-mediated diseases in particular and the evolution of the adaptive immune system in general.” Google scholar: https://scholar.google.ch/citations?hl=en&user=-Tf6dCkAAAAJ
Speaker: Associate Prof Marco Donia, MD, PhD
Title: Cancer Immunotherapy: merging research and real world evidence
Date: Thursday, June 10, 14-15:00
Bio: Dr. Marco Donia is Clinician-Scientist (50% staff specialist and 50% junior research group leader), Center for Cancer Immune Therapy-CCIT, Department of Oncology, Copenhagen University Hospital Herlev, Denmark and a Clinical Associate Professor, Department of Clinical Medicine, University of Copenhagen, Denmark. List of publications. https://orcid.org/0000-0003-4966-9752. He is also a Lundbeck fellow with a project to identify and study the effect of the substances that stimulate cancer cells and to attempt to minimise their effect.
Speaker: Prof Susan Rooijakkers, MD, PhD
‘Antibodies against bacterial infections: from basic insights to therapies’
Date: Thursday, May 20, 14-15:00
Bio: Prof Suzan Rooijakkers is head of the Bacterial Infections and Immunity. Suzan Rooijakkers is full professor at the Department of Medical Microbiology at the University Medical Center in Utrecht. She is an expert in the field of Bacterial Infections and Immunity. During her PhD and postdocs, Rooijakkers played an important role in the discovery of bacterial immune escape mechanisms. She identified several molecules secreted by S. aureus to modulate human complement and neutrophils (Nature Immunology (2005 & 2009), patent (2006), Journal of Experimental Medicine (2007), PNAS (2014)). After completing a postdoc at UCSD San Diego (USA), Rooijakkers established an independent research group focused at understanding the molecular interplay between bacteria and the human immune system, with the ultimate aim to translate research findings into new strategies for treatment of infectious disease. Her current research group (8 PhD students, 3 Postdocs and 1 technician) mainly focuses on the following main themes: How the human immune system kills bacteria and Antibody therapies against bacteria.
Speaker: Jeremy Swann
‘Adaptive disarmament: the immunogenetics of deep-sea anglerfish’
Date: Thursday, Feb 25 at 14.00.
[Bio: Dr. Swann obtained his PhD from the University of Melbourne under the supervision of Mark Smyth. He is a group leader at the MPI of Immunobiology and Epigenetics (Freiburg, Germany). His latest article is on The immunogenetics of sexual parasitism, https://science.sciencemag.org/content/369/6511/1608]
Speaker: Dr. Roger Geiger (https://www.geigerlab.org/)
‘Systems analyses of anti-tumor T cell responses’
Date: Thursday, Jan 28 at 14.00.
[Bio: Dr. Geiger obtained his PhD from the ETH Zürich under the supervision of Ari Helenius. He received postdoctoral training in immunology with Antonio Lanzavecchia and in proteomics with Matthias Mann. Since 2017 Roger is an independent group leader at the Institute for Research in Biomedicine, CH. His groups works mainly on T-cell metabolism. He was awarded an ERCStG in 2018. His latest article is on Dynamics in protein translation sustaining T cell preparedness, https://www.nature.com/articles/s41590-020-0714-5].
Speaker: María Casanova Acebes, PhD
‘Lineage tracing reveals the pro-tumorigenic niche role of tissue resident macrophages in early lung cancer lesions’
Date: Thursday, April 8 at 14.00
Dr. María Casanova Acebes is head of the Cancer Immunity Laboratory at www.cnio.es. She completed her postdoctoral training in the laboratory of Miriam Merad. Here latest work has been published in Nature Communications: https://www.nature.com/articles/s41467-020-15371-0: RXRs control serous macrophage neonatal expansion and identity and contribute to ovarian cancer progression.